AGREEMENT ON ASSIGNMENT AND COMPENSATION FOR INVENTIONS
Exhibit
10.1
THIS
AGREEMENT, effective July 2, 2008, is by
and between The ▇▇▇▇▇▇▇ Corporation, a corporation of the State of Pennsylvania,
having a principal place of business at Kells Building, ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇ of America, (hereinafter
"▇▇▇▇▇▇▇") and ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, a citizen of the United States of
America, residing at ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇,
▇▇▇▇▇▇ ▇▇▇▇▇▇ of America (hereinafter "▇▇. ▇▇▇▇▇▇▇▇▇▇").
WHEREAS
▇▇. ▇▇▇▇▇▇▇▇▇▇ had certain concepts and/or inventions prior to the date of him
becoming an employee of The ▇▇▇▇▇▇▇ Corporation.
WHEREAS
▇▇▇▇▇▇▇ desires to obtain entire right, title and interest in and to the
▇▇▇▇▇▇▇▇▇▇ concepts and/or inventions and to pursue such concepts and/or
inventions through investment and the work of ▇▇. ▇▇▇▇▇▇▇▇▇▇, and in and to any
patent applications and patents relating to the subject matter of such concepts
and/or inventions in any and all countries.
WHEREAS
▇▇. ▇▇▇▇▇▇▇▇▇▇ assigned the entire right, title and interest in and to said
concepts and/or inventions, and in and to any patent applications and patents
relating to the subject matter of said inventions in any and all countries by
virtue of executed assignment documents.
WHEREAS
▇▇▇▇▇▇▇ agreed to compensate ▇▇. ▇▇▇▇▇▇▇▇▇▇ for assigning the entire right,
title and interest into ▇▇. ▇▇▇▇▇▇▇▇▇▇'▇ concepts and/or inventions made prior
to the date he became an employee of ▇▇▇▇▇▇▇.
WHEREAS
▇▇▇▇▇▇▇ has made a substantial investment of capital, labor and other resources
into the development of the concepts and/or inventions made by ▇▇. ▇▇▇▇▇▇▇▇▇▇
while an employee of ▇▇▇▇▇▇▇, as well as patenting the inventions during the
period of his employment by ▇▇▇▇▇▇▇.
THEREFORE,
the parties agree as follows:
ARTICLE I
- DEFINITIONS
|
1.0
|
▇▇▇▇▇▇▇
and ▇▇. ▇▇▇▇▇▇▇▇▇▇ are hereunder commonly reviewed to as "parties" (in
singular and plural usage, as required by the
context.
|
|
1.1
|
Terms
in this agreement (other than the name of the parties and Article
headings) which are set forth in upper case letters have the meanings
established for such terms in the succeeding paragraphs of this ARTICLE
I.
|
|
1.2
|
INVENTIONS
made by ▇▇. ▇▇▇▇▇▇▇▇▇▇ prior to or after the date of his employment by ▇▇▇▇▇▇▇, which are
specifically set forth in Exhibit A
hereto.
|
|
1.3
|
PATENTS
means the patents listed in Exhibit A hereto, as well as any
patent granted on the basis of any patent application listed in
Exhibit A hereto, or which claims priority to any patent application
listed in Exhibit A hereto under the relevant provisions of the Paris
Convention, as well as reexaminations and reissues thereof which may
be granted upon said application and upon any and all continuation or
divisional applications for patents for said inventions, in and
for the United States and foreign
countries.
|
|
1.4
|
ROYALTY-BEARING
PRODUCT means any product which embodies one or more of the
INVENTIONS and comes within the scope of any unexpired claim of any
of the PATENTS.
|
|
1.5
|
LICENSING
COSTS means costs incurred by ▇▇▇▇▇▇▇ to obtain any licenses from
third parties necessary to make, use, sell or offer to sell
ROYALTY- BEARING
PRODUCTS.
|
|
1.6
|
TITLE
DEFENSE COSTS means costs incurred by ▇▇▇▇▇▇▇ to defend its title
to the INVENTIONS, any patent applications for protection of the
INVENTIONS, and/or any PATENTS from any challenge to ▇▇▇▇▇▇▇'▇ title
made by a third party.
|
|
1.7
|
NET
SALES, according to Generally Accepted Accounting Principles
(GAAP), in respect to ROYALTY-BEARING PRODUCTS sold means amounts
actually collected after deduction of certain items, such as, but is
not limited to, regular trade and quantity discounts, returns and
allowances, co-operative incentives, less LICENSING COSTS and TITLE
DEFENSE COSTS.
|
ARTICLE
II - REPRESENTATIONS, WARRANTIES AND LIMITATIONS
|
2.1
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants in respect to the PATENTS that ▇▇.
▇▇▇▇▇▇▇▇▇▇ has the legal right to extend the rights granted to ▇▇▇▇▇▇▇ in
this agreement and in the assignment agreements, which agreements are
incorporated by reference, and that ▇▇. ▇▇▇▇▇▇▇▇▇▇ has not made and will
not make any commitments to others inconsistent with or in derogation of
such rights.
|
|
2.2
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants that ▇▇. ▇▇▇▇▇▇▇▇▇▇ has not published,
caused to be published, publicly used or disclosed, caused to be publicly
used or disclosed, offered for sale or caused to be offered for sale, any
of the INVENTIONS prior to the date of filing of the first United States
patent application which discloses the respective one of the
INVENTIONS.
|
|
2.3
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants that he is the original, first and
sole inventor of each of the
INVENTIONS.
|
|
2.4
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants that he has disclosed to ▇▇▇▇▇▇▇
all information in his possession
pertaining to the INVENTIONS which may be necessary or useful
for the preparation and filing of patent applications for the protection of such INVENTIONS,
which may be required for the patent applicant to satisfy its duty of disclosure
to any of the patent offices in which a patent application for protection of any
of said INVENTIONS is filed, and which may be required to determine ownership of said INVENTIONS
under the applicable
law.
|
|
2.5
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants that he has been advised of his right
to have this agreement reviewed by independent counsel of his own
choosing and that he has, in fact, had this agreement reviewed by
independent counsel or has freely chosen to waive this
right.
|
|
2.6
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ represents and warrants that he has not relied on
any representations made by counsel for ▇▇▇▇▇▇▇ in entering into this
agreement.
|
|
2.7
|
Nothing in this agreement shall be construed as: |
| (a) A requirement that either party shall file any patent application(s), secure any patent(s), or maintain any patent(s) in force, | |
| (b) An obligation to bring or prosecute actions or suits against third parties for infringement of any patent, or | |
| (c) Granting by implication, estoppel or otherwise, any licenses or rights under any patents other than PATENTS. |
ARTICLE
III - FILING AND PROSECUTION OF APPLICATIONS
|
3.1
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ shall, from time to time, on request, supply such
additional information as may be necessary or desirable to facilitate
prosecution of patent applications for the protection of the
INVENTIONS.
|
|
3.2
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ shall, each time a request is made and without undue
delay, execute and deliver such papers as may be necessary or
desirable to perfect the title to the INVENTIONS, and any patent
applications or PATENTS to ▇▇▇▇▇▇▇, its successors, assigns, nominees
or legal representatives.
|
|
3.3
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ shall testify in any legal proceedings, sign all lawful
papers, execute all disclaimers and divisional, continuing, reissue
and foreign applications, make all rightful oaths, and generally do
everything possible to aid ▇▇▇▇▇▇▇, its successors, assigns, nominees
or legal representatives, to obtain and enforce, for its or their own
benefit, proper patent protection for the INVENTIONS in any and all
countries.
|
|
3.4
|
▇▇▇▇▇▇▇ will accept financial responsibility for: |
|
(a)
|
Preparation,
by a patent lawyer in independent practice who shall be nominated by
▇▇▇▇▇▇▇, of a patent application or applications on
patentable aspects of the
INVENTIONS,
|
|
(b)
|
Filing,
upon execution by ▇▇. ▇▇▇▇▇▇▇▇▇▇, of such patent application
or applications, and
|
|
(c)
|
Prosecution
by such nominated lawyer of the application or
applications.
|
|
3.5
|
▇▇▇▇▇▇▇
may, at any time, decide not to file a patent application, decide not to
further prosecute a patent application, or decide not to maintain a
patent, at its own
discretion.
|
ARTICLE
IV - ASSIGNMENT OF RIGHTS
|
4.1
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ shall assign all right, title and interest in and to
said INVENTIONS, and in and to any patent applications for protection
of said INVENTIONS, including the right to claim priority to the
patent applications in any foreign patent application entitled to
claim such priority under national law, international conventions,
treaties or otherwise, and any and all continuations, divisions, and
renewals of, and substitutes for, said applications, and in, to
and under any and all patents which may be granted on or as a result
of said patent applications in any and all countries, and any reissue
or reissues, or extension or extensions of said patents, and
authorize ▇▇▇▇▇▇▇ to file in ▇▇. ▇▇▇▇▇▇▇▇▇▇'▇ name, applications for
patents in all countries, the same to be held and enjoyed by ▇▇▇▇▇▇▇,
its successors, assigns, nominees or legal representatives, to the full
end of the term or terms for which said patents, respectively, may be
granted, reissued or extended, as fully and entirely as the same
would have been held and enjoyed by me had this assignment, sale and
transfer not been made.
|
|
4.2
|
▇▇▇▇▇▇▇
shall have the right to bring suit in its own name, or, if required by
law, jointly with ▇▇. ▇▇▇▇▇▇▇▇▇▇, at its own expense and on its own
behalf, for infringement of the PATENTS. In any such suit, ▇▇▇▇▇▇▇
shall have the right to enjoin for infringement and to collect for
its use, damages, profits, and awards of whatever nature recoverable
for such infringement, and to settle any claim or suit for infringement of
the PATENTS by granting the infringing party a license under one or
more of the PATENTS. ▇▇▇▇▇▇▇ shall pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ five
percent (5%) of the excess of any recoveries over expenses in such
suits.
|
ARTICLE V
- COMPENSATION AND REPORTS
|
5.1
|
In
consideration of, and as full compensation for, the covenants made in
this agreement, ▇▇▇▇▇▇▇ shall pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ compensation in
the amount of five percent (5%) of NET SALES, of ROYALTY-BEARING
PRODUCTS.
|
|
5.2
|
▇▇▇▇▇▇▇
shall pay compensation to ▇▇. ▇▇▇▇▇▇▇▇▇▇ biannually, and shall
have thirty (30) days from the end of each six-month compensation
period to pay the compensation to ▇▇. ▇▇▇▇▇▇▇▇▇▇ and provide the
report specified in paragraph 5.4 of this agreement. As long as ▇▇.
▇▇▇▇▇▇▇▇▇▇ is an employee of The ▇▇▇▇▇▇▇ Corporation, The ▇▇▇▇▇▇▇
Corporation shall withhold all applicable and appropriate federal, state
and local taxes.
|
|
5.3
|
▇▇▇▇▇▇▇
shall pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ five percent (5%) of any
Royalty-Bearing License other than a license to a joint venture or a
partnership. ▇▇▇▇▇▇▇ shall have the sole discretion to determine the
terms of the license. If a Royalty-Bearing License is sold by The
▇▇▇▇▇▇▇ Corporation and consideration paid to ▇▇. ▇▇▇▇▇▇▇▇▇▇ under
this paragraph, there shall be no further obligation to pay royalties
under Article V.
|
|
5.4
|
▇▇▇▇▇▇▇
shall provide a report to ▇▇. ▇▇▇▇▇▇▇▇▇▇, along with the
compensation set forth in paragraph 5.1 above, which includes
sufficient information to verify the correctness of the amount of
compensation provided to ▇▇. ▇▇▇▇▇▇▇▇▇▇ for the previous six-month
period.
|
|
5.5
|
▇▇.
▇▇▇▇▇▇▇▇▇▇ shall have the right at his expense to audit annually the
books and records relating to the computation of this consideration
paid to him under this
article.
|
ARTICLE
VI - TRANSFER OF RIGHTS AND OBLIGATIONS
|
6.1
|
The
rights and obligations of ▇▇▇▇▇▇▇ under this agreement shall pass to
any assigns for the benefit of creditors of ▇▇▇▇▇▇▇, and to any
receiver of ▇▇▇▇▇▇▇'▇ assets, or to any person or corporation
succeeding to ▇▇▇▇▇▇▇'▇ entire business as a result of sale,
consolidation, reorganization or otherwise, provided such assignee,
receiver, person or legal entity shall, without delay, accept in writing
the provisions of this agreement, and agree in all respects to be
bound thereby in the place and stead of
▇▇▇▇▇▇▇.
|
|
6.2
|
▇▇▇▇▇▇▇
may assign the rights and obligations to any person or legal
entity, provided such assignee, receiver, person or legal entity
shall, without delay, accept in writing the provisions of this
agreement, and agree in all respects to be bound thereby in the place
and stead of ▇▇▇▇▇▇▇.
|
ARTICLE
VII - TERM AND TERMINATION
|
7.1
|
This
agreement may only be terminated in the event of a material breach by
either party in the due observance or performance of any covenant,
condition or limitation of this agreement, but only if such material
breach has not been remedied within thirty (30) days after receipt
from the non-breaching party of written notice of such material
breach.
|
|
7.2
|
If,
in any proceeding in which the validity, infringement, ownership or
priority of invention of any claim of any PATENT is in issue, a
judgment or decree is entered which becomes not further renewable
through the exhaustion of all
|
permissible
applications for rehearing or review by a superior tribunal, or through the
expiration of the time permitted for such applications (hereinafter referred to
as "an irrevocable judgment"), the construction placed upon any such claim by
such irrevocable judgment shall thereafter be followed, not only as to such
claims but as to all claims to which such construction applies, with respect to
acts occurring thereafter, and, if such irrevocable judgment holds any claim
invalid or is adverse to the patent as to inventorship or ownership, ▇▇▇▇▇▇▇
shall be relieved from including in its reports, products sold covered only by
such claim or by any broader claim to which such irrevocable judgment is
applicable, and from the performance of those other acts which may be required
by this agreement only because of any such claim: provided however, that if
there are two or more conflicting irrevocable judgments with respect to the same
claim, the decision of the higher tribunal shall be followed thereafter, but if
the tribunals be of equal dignity, the decision more favorable to the claim
shall be followed until the less favorable decision has been followed by the
irrevocable judgment of a tribunal of at least equal dignity. In the event of
conflicting irrevocable judgments by the same court, the latest judgment shall
control.
ARTICLE
VIII - NOTICES, APPLICABLE LAW, ARBITRATION
|
8.1
|
Any
notice, report or payment provided for in this agreement shall be
deemed sufficiently given when sent by certified or registered mail
address to the party for whom intended at the address given at the
outset of this agreement or at such changed address as the party
shall have specified by written
notice.
|
|
8.2
|
This
agreement shall be construed, interpreted, and applied in accordance with
the laws of the Commonwealth of
Pennsylvania.
|
|
8.3
|
Any
controversy or claim arising under or related to this agreement shall
be settled by arbitration in accordance with the applicable
arbitration rules of the American Arbitration Association before a
single arbitrator selected in accordance with those rules, and
judgment upon the award rendered by the arbitrator may be entered in
any court having jurisdiction
thereof.
|
ARTICLE
IX - INTEGRATION
|
9.1
|
This
instrument, and the Exhibit A hereto, contain the entire agreement between
the parties and supersedes all preexisting oral agreements and any other
written agreements, other than Assignment Agreements, respecting the
subject matter of this agreement Any representation, promise, or condition
in connection with such subject matter which is not incorporated in this
agreement shall not be binding upon either party. No modification,
renewal, extension, waiver, or termination shall be binding upon the party
against whom the enforcement of such modification, renewal, extension,
waiver or termination is sought, unless made in writing and signed on
behalf of such party.
|
IN
WITNESS WHEREOF, each of the parties intending to be legally bound hereby has
caused this agreement to be executed and duly sealed in duplicate
originals.
|
The
▇▇▇▇▇▇▇ Corporation
|
|||||
| By | /s/ ▇▇▇ ▇. ▇▇▇▇▇▇▇ | /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ | |||
| ▇▇▇ ▇. ▇▇▇▇▇▇▇, President | ▇▇. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ | ||||
|
|
|||||
|
Attest:
|
|||||
| /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ |
|
||||
|
▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, Secretary
|
|||||
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-333
|
QUIG-1001US
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
09/740,811
|
12/21/2000
|
6,555,573
|
4/29/2003
|
ISSUED
|
3/27/2021
|
|
QR-333
|
QUIG-1001USDIV1
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
10/369,025
|
2
/19/2003
|
PUBLISHED
|
12/21/2020
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
2002231095
|
12/19/2001
|
2002231095
|
11/24/2005
|
ISSUED
|
12/19/2021
|
|
QR-333
|
QUIG-1001CA
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
2,431,079
|
12/19/2001
|
PENDING
|
12/19/2021
|
||
|
QR-333
|
QUIG-1001EP
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
01991367.2
|
12/19/2001
|
PUBLISHED
|
12/19/2021
|
||
|
QR-333
|
QUIG-1001IL
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
156549
|
12/19/2001
|
PENDING
|
12/19/2021
|
||
|
QR-333
|
QUIG-1001IN
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
00870/DELNP/2003
|
12/19/2001
|
PENDING
|
12/19/2021
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
2002-550919
|
12/19/2001
|
PENDING
|
12/19/2021
|
||
|
QR-333
|
QUIG-1001MX
|
METHOD
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
PA/A/2003/005672
|
12/19/2001
|
236311
|
4/28/2006
|
ISSUED
|
12/19/2021
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
526041
|
12/19/2001
|
526041
|
5/12/2005
|
ISSUED
|
12/19/2021
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇
AND COMPOSITION FOR THE TOPICAL TREATMENT OF DIABETIC
NEUROPATHY
|
2003/4247
|
12/19/2001
|
2003/4247
|
7/28/2004
|
ISSUED
|
12/19/2021
|
|
QR-333
|
QUIG-1011US
|
METHODS
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
10/288,825
|
11/6
/2002
|
7,083,813
|
8/1/2006
|
ISSUED
|
▇/▇/▇▇▇▇
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
11/165,151
|
6
/23/2005
|
PUBLISHED
|
11/6/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
METHODS
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
2002352501
|
11/6
/2002
|
2002352501
|
ISSUED
|
▇▇/▇/▇▇▇▇
|
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
2,470,603
|
11/6
/2002
|
PENDING
|
▇▇/▇/▇▇▇▇
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
02789474.0
|
11/6
/2002
|
PUBLISHED
|
▇▇/▇/▇▇▇▇
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
162505
|
11/6
/2002
|
PENDING
|
▇▇/▇/▇▇▇▇
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
1683/DELNP/2004
|
11/6
/2002
|
PENDING
|
11/6/2022
|
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-333
|
QUIG-1011JP
|
METHODS
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
2003-554096
|
11/6
/2002
|
PUBLISHED
|
11/6/2022
|
||
|
QR-333
|
QUIG-1011MX
|
METHODS
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
PA/A/2004/006039
|
11/6
/2002
|
PENDING
|
▇▇/▇/▇▇▇▇
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
533439
|
11/6
/2002
|
533439
|
10/12/2006
|
ISSUED
|
11/6/2022
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
METHODS
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
93102875
|
11/6
/2002
|
PUBLISHED
|
▇▇/▇/▇▇▇▇
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
▇▇▇▇▇▇▇
FOR THE TREATMENT OF PERIPHERAL NEURAL AND VASCULAR
AILMENTS
|
2004/4614
|
11/6
/2002
|
2004/4614
|
10/28/2005
|
ISSUED
|
11/6/2022
|
|
QR-334
|
QUIG-1007US
|
MEDICAL
COMPOSITION AND METHOD OF USING IT
|
09/923,090
|
8 /6
/2001
|
6,592,896
|
7/15/2003
|
ISSUED
|
8/6/2021
|
|
QR-334
|
QUIG-1007USCIP
|
NUTRITIONAL
SUPPLEMENTS AND METHODS OF USING IT
|
10/122,991
|
4
/15/2002
|
6,596,313
|
7/22/2003
|
ISSUED
|
8/6/2021
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENTS AND METHODS OF USING IT
|
2002332464
|
8 /6
/2002
|
2002332464
|
2/22/2007
|
ISSUED
|
8/6/2022
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
2,455,391
|
8 /6
/2002
|
PENDING
|
8/6/2022
|
||
|
QR-334
|
QUIG-1007CN
|
NUTRITIONAL
SUPPLEMENTS AND METHODS OF USING SAME
|
02814148.2
|
8 /6
/2002
|
PENDING
|
8/6/2022
|
||
|
QR-334
|
QUIG-1007IN
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
0004/MUMNP/2004
|
8 /6
/2002
|
PENDING
|
8/6/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
2003-518442
|
8 /6
/2002
|
PENDING
|
8/6/2022
|
||
|
QR-334
|
QUIG-1007IL
|
NUTRITIONAL
SUPPLEMENTS AND METHODS OF USING SAME
|
159357
|
8 /6
/2002
|
159357
|
11/21/2006
|
ISSUED
|
8/6/2022
|
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
530187
|
8 /6
/2002
|
PUBLISHED
|
8/6/2022
|
||
|
QR-334
|
QUIG-1007KR
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
▇▇-▇▇▇▇-▇▇▇▇▇▇▇
|
8 /6
/2002
|
PENDING
|
8/6/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENT AND METHODS OF USING IT
|
2003/9802
|
8 /6
/2002
|
2003/9802
|
7/28/2004
|
ISSUED
|
8/6/2022
|
|
QR-335
|
QUIG-1006US
|
COMPOSITION
AND METHOD FOR REDUCING RADIATION DERMATITIS
|
09/993,003
|
11/6/2001
|
6,753,325
|
6/22/2004
|
ISSUED
|
11/6/2021
|
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-335
|
QUIG-06USCIP4
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
10/288,761
|
11/6/2002
|
PUBLISHED
|
11/6/2021
|
||
|
QR-335
|
QUIG-1006AU2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
▇▇▇▇▇▇▇▇▇▇
|
11/6/2002
|
PENDING
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006CA2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
2,465,888
|
11/6/2002
|
PENDING
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006CN2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
02826541.6
|
11/6/2002
|
PUBLISHED
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006EP2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
02803307.4
|
11/6/2002
|
PUBLISHED
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006HK2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
05111253.4
|
12/8/2005
|
PUBLISHED
|
12/8/2025
|
||
|
QR-335
|
QUIG-1006IL2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
161775
|
11/6/2002
|
PENDING
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006IN2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
01160/DELNP/2004
|
11/6/2002
|
PENDING
|
11/6/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
2003-552220
|
11/6/2002
|
PUBLISHED
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006MX2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
PA/A/2004/004377
|
11/6/2002
|
PUBLISHED
|
11/6/2022
|
||
|
QR-335
|
QUIG-1006NZ2
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
532775
|
11/6/2002
|
PUBLISHED
|
11/6/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
TOPICAL
COMPOSITIONS AND METHODS FOR TREATMENT OF ADVERSE EFFECTS OF IONIZING
RADIATION
|
2004/3365
|
11/6/2002
|
2004/3365
|
5/31/2006
|
ISSUED
|
11/6/2022
|
|
QR-336
|
QUIG-1006USCIP
|
COMPOSITION
FOR RADIATION DERMATITIS AND EXPOSURE
|
10/045,790
|
1/14/2002
|
PUBLISHED
|
|||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
2002309615
|
5/1/2002
|
PENDING
|
5 /1
/2022
|
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-336
|
QUIG-1006CA
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
2,465,945
|
5/1/2002
|
PENDING
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006CN
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
02822057.9
|
5 /1
/2002
|
PUBLISHED
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006EP
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
02736624.4
|
5 /1
/2002
|
PUBLISHED
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006IL
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
161774
|
5 /1
/2002
|
PENDING
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006IN
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
01165/DELNP/2004
|
5 /1
/2002
|
PENDING
|
5 /1
/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
2003-541744
|
5 /1
/2002
|
PUBLISHED
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006MX
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
PA/A/2004/004376
|
5 /1
/2002
|
PUBLISHED
|
5 /1
/2022
|
||
|
QR-336
|
QUIG-1006NZ
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
532774
|
5 /1
/2002
|
PENDING
|
5 /1
/2022
|
||
|
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇
|
NUTRITIONAL
SUPPLEMENTS AND METHODS FOR PREVENTION, REDUCTION AND TREATMENT OF
RADIATION INJURY
|
2004/3364
|
5 /1
/2002
|
PENDING
|
5 /1
/2022
|
||
|
QR-433
|
QUIG-07USDIV2
|
COMPOSITIONS
AND METHODS FOR TREATMENT OF RHINOVIRUS
|
11/553,656
|
10/27/2006
|
PENDING
|
8 /6
/2021
|
||
|
QR-434
|
QUIG-07USCON4
|
COMPOSITIONS
AND METHODS FOR TREATMENT OF HERPES
|
11/371,974
|
3 /9
/2006
|
7,175,987
|
2
/13/2007
|
ISSUED
|
11/5
/2021
|
|
QR-435
|
QUIG-07USCIP2
|
ANTI-MICROBIAL
COMPOSITIONS AND METHODS OF USING SAME
|
10/359,889
|
2 /6
/2003
|
PUBLISHED
|
8 /6
/2021
|
||
|
QR-440
|
QUIG-07USDIV1
|
NUTRITIONAL
SUPPLEMENTS AND METHODS OF USING SAME
|
10/421,276
|
4
/23/2003
|
6,827,945
|
12/7
/2004
|
ISSUED
|
8 /6
/2021
|
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
COMPOSITIONS
AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES
|
11/012,764
|
12/14/2004
|
7,166,435
|
1
/23/2007
|
ISSUED
|
11/5
/2021
|
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
2003256736
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
2,495,447
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
03818966.6
|
7
/24/2003
|
PUBLISHED
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
03766897.7
|
7
/24/2003
|
PUBLISHED
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
05112150.6
|
12/29/2005
|
PUBLISHED
|
12/29/2025
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
166608
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
258/DELNP/2005
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
2004-526143
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
|
QUIG
REF.
|
MATTER
NO.
|
TITLE
|
SERIAL
NO.
|
FILE
DATE
|
PATENT
NO.
|
ISSUE
DATE
|
STATUS
|
EXPIRATION
|
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
2005-7002080
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
QUIG-1007MX2
|
ANTI-MICROBIAL
METHODS AND COMPOSITIONS
|
PA/A/2005/001051
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
537821
|
7
/24/2003
|
PENDING
|
7
/24/2023
|
||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇
|
COMPOSITIONS
AND METHODS FOR REDUCING THE TRANSMISSIVITY OF ILLNESSES
|
PCT/US2005/045218
|
12/14/2005
|
PUBLISHED
|
|||
|
QR-433-437
QR-439
QR-441-441(a)
▇▇-▇▇▇
▇▇-▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇
|
▇▇▇▇-▇▇▇▇▇▇▇▇▇
METHODS AND COMPOSITIONS
|
2005/0517
|
7
/24/2003
|
2005/0517
|
12/28/2005
|
ISSUED
|
7
/24/2023
|